prednisone has been researched along with Common Bile Duct Diseases in 1 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Common Bile Duct Diseases: Diseases of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pancreatitis is the most common and serious complication of diagnostic and therapeutic ERCP." | 2.72 | Risk factors for post-ERCP pancreatitis: a prospective multicenter study. ( Aliperti, G; Barnett, J; Cheng, CL; Dua, KS; Fogel, EL; Frakes, JT; Freeman, M; Geenen, J; Goff, J; Jones, W; Lazzell-Pannell, L; Lehman, GA; Parker, H; Rashdan, A; Ryan, M; Sherman, S; Silverman, WB; Temkit, M; Uzer, M; Watkins, JL; Yakshe, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, CL | 1 |
| Sherman, S | 1 |
| Watkins, JL | 1 |
| Barnett, J | 1 |
| Freeman, M | 1 |
| Geenen, J | 1 |
| Ryan, M | 1 |
| Parker, H | 1 |
| Frakes, JT | 1 |
| Fogel, EL | 1 |
| Silverman, WB | 1 |
| Dua, KS | 1 |
| Aliperti, G | 1 |
| Yakshe, P | 1 |
| Uzer, M | 1 |
| Jones, W | 1 |
| Goff, J | 1 |
| Lazzell-Pannell, L | 1 |
| Rashdan, A | 1 |
| Temkit, M | 1 |
| Lehman, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Transdermal Glyceryl-Trinitrate and Parecoxib (Valdecoxib) for the Prevention of Post -ERCP Pancreatitis[NCT00419549] | Phase 2/Phase 3 | 371 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Because one of the drugs Valdecoxib was withdrawn due to safety concerns.) | ||
| Feasibility Study of a Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis[NCT01758549] | 62 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for prednisone and Common Bile Duct Diseases
| Article | Year |
|---|---|
Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Topics: Adult; Age Distribution; Aged; Analysis of Variance; Cholangiopancreatography, Endoscopic Retrograde | 2006 |
Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Topics: Adult; Age Distribution; Aged; Analysis of Variance; Cholangiopancreatography, Endoscopic Retrograde | 2006 |
Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Topics: Adult; Age Distribution; Aged; Analysis of Variance; Cholangiopancreatography, Endoscopic Retrograde | 2006 |
Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Topics: Adult; Age Distribution; Aged; Analysis of Variance; Cholangiopancreatography, Endoscopic Retrograde | 2006 |